Supplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 | AMiner
Supplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 13. Assessment of the ability of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47, and a IgG1 isotype control antibody to induce direct apoptosis of THP1 cells, as assessed by flow cytometry of Annexin V cell surface expression.
原文链接
分享
引用
